LepVax

Country: Brazil

Location(s): Rio de Janeiro

ALM is currently conducting a safety trial (Phase 1b/2a) to transition the defined subunit vaccine, LepVax, into M. leprae-infected individuals in a leprosy-endemic country.

ILEP Members involved

American Leprosy Missions
Melissa Edmiston

DAHW (German Leprosy and Tuberculosis Relief Association)


Effect Hope


Fondation Raoul Follereau


NLR

Partners

MoH, Fiocruz

Physical facilities involved